Effects of Optimized Antiplatelet Treatment After Percutaneous Coronary Intervention
Information source: Shenyang Northern Hospital
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Ischemic Heart Disease; Acute Coronary Syndromes
Intervention: aspirin, clopidogrel and cilostazol (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Shenyang Northern Hospital Official(s) and/or principal investigator(s):
Yaling Han, M.D., Principal Investigator, Affiliation: Shenyang Northern Hospital
Overall contact:
Yi Li, M.D., Phone: 86-24-2305-1587, Email: doctorliyi@126.com
Summary
Effects of dual antiplatelet therapy with aspirin and clopidogrel after percutaneous coronary
intervention has been proven. However, patients with low response to those agents are
reported be associated with adverse clinical outcomes. We suppose that optimized antiplatelet
therapy for individual patients based on platelet function assay may improve long-term
outcomes especially in patients with high risk of thrombosis. In this prospective randomized
study, patients in control group all receive standard dual antiplatelet therapy, and patients
in optimized group receive different antiplatelet therapy according to risk stratification.
Clinical Details
Official title: Pilot Study of Personal Optimized Antiplatelet Treatment After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes
Study design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: major adverse cardiac and cerebral events at 1 year
Secondary outcome: hemorrhage events at 1 year
Eligibility
Minimum age: 35 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- non-ST-segment elevated acute coronary syndromes
- patients undergoing selective or emergent PCI
Exclusion Criteria:
- administration of clopidogrel or ticlopidine within 2 weeks
- ST-segment elevated myocardial infarction
- contraindications of antiplatelet therapy
- history of intracranial bleeding
- known bleeding disorders
- severe liver or kidney disease
Locations and Contacts
Yi Li, M.D., Phone: 86-24-2305-1587, Email: doctorliyi@126.com
Northern Hospital, Shenyang, Liaoning 110016, China; Recruiting
Yi Li, M.D., Phone: 86-24-2305-1587
Additional Information
Starting date: June 2006
Last updated: November 28, 2006
|
